Abbvie Inc   (ABBV)
Other Ticker:  
    Sector  Healthcare    Industry Biotechnology & Drugs
   Industry Biotechnology & Drugs
   Sector  Healthcare

Abbvie Inc 's



ABBV Sales vs. its Competitors Q2 2020

Comparing the results to its competitors, Abbvie Inc reported Total Revenue increase in the 2 quarter 2020 by 26.29 % year on year.
The sales growth was above Abbvie Inc 's competitors average revenue growth of 3.51 %, recorded in the same quarter.

List of ABBV Competitors

Revenue Growth Comparisons

Net Income Comparison

Abbvie Inc recorded net loss and most of company's competitors saw decline in earnings by -51.28 %

<<  More on ABBV Income Comparisons

Abbvie Inc 's Comment on Competitors and Industry Peers

The markets for AbbVie's products are highly competitive. AbbVie competes with other research-based pharmaceuticals and biotechnology companies that discover, manufacture, market, and sell proprietary pharmaceutical products and biologics. For example, HUMIRA competes with a number of anti-TNF and other products that are approved for a number of disease states and AbbVie's virology products compete with protease inhibitors and other anti-HIV treatments. The search for technological innovations in pharmaceutical products is a significant aspect of competition. The introduction of new products by competitors and changes in medical practices and procedures can result in product obsolescence. Price is also a competitive factor. In addition, the substitution of generic pharmaceutical products for branded pharmaceutical products creates competitive pressures on AbbVie's products that do not have patent protection.

Biosimilars. Competition for AbbVie's biologic products is affected by the approval of follow-on biologics, also known as "biosimilars." Biologics have added major therapeutic options for the treatment of many diseases, including some for which therapies were unavailable or inadequate. The advent of biologics has also raised complex regulatory issues and significant pharmacoeconomic concerns because the cost of developing and producing biologic therapies is typically dramatically higher than for conventional (small molecule) medications, and because many expensive biologic medications are used for ongoing treatment of chronic diseases, such as rheumatoid arthritis or inflammatory bowel disease, or for the treatment of previously untreatable cancer. Significant investments in biologics infrastructure and manufacturing are necessary to produce biologic products, as are significant investments in marketing, distribution, and sales organization activities, which may limit the number of biosimilar competitors.

In the United States, the FDA regulates biologics under the Federal Food, Drug, and Cosmetic Act, the Public Health Service Act, and implementing regulations. While the enactment of federal health care reform legislation in March 2010 was meant to provide a pathway for approval of biosimilars under the Public Health Service Act, recent regulatory guidance suggests that the approval process for biosimilars will be far more extensive than the approval process for generic or other follow-on versions of small molecule products, in order to ensure that the safety and efficacy of biosimilars is highly similar to that of an original biologic, such as HUMIRA. Ultimate approval by the FDA is dependent upon many factors, including a showing that the biosimilar is "highly similar" to the original product and has no clinically meaningful differences from the original product in terms of safety, purity, and potency. The types of data that could ordinarily be required in an application to show similarity would include analytical data and studies to demonstrate chemical similarity, animal studies (including toxicity studies), and clinical studies. Applicable regulations also require that the biosimilar must be for the same indication as the original biologic and involve the same mechanism of action, and that the manufacturing facility meets the standards necessary to assure that the biosimilar is safe, pure, and potent.

Furthermore, the new law provides that only a biosimilar product that is deemed to be "interchangeable" may be substituted for the original biologic product without the intervention of the health care provider who prescribed the original biologic product. To prove that a biosimilar product is interchangeable, the applicant must demonstrate that the product can be expected to produce the same clinical results as the original biologic product in any given patient, and if the product is administered more than once in a patient, that safety risks and potential for diminished efficacy of alternating or switching between the use of the interchangeable biosimilar biologic product and the original biologic product is no greater than the risk of using the original biologic product without switching. The new law is only beginning to be interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning will likely be subject to substantial uncertainty for years to come.


HUMIRA Segment Market Share Q2 2020

Despite revenue growth of 12.04 % in HUMIRA segment, Abbvie Inc lost market share within this segment.

<<  More on ABBV Market Share.


Kaletra Segment Market Share Q2 2020

despite revenue deterioration, Abbvie Inc inceased its market share in this segment.

company inceased its market share in this segment to approximate 9.14 %.

<<  More on ABBV Market Share.


Lupron Segment Market Share Q2 2020

With modest revenue growth of 2.55 % within Lupron segment, Abbvie Inc increased its market share.

<<  More on ABBV Market Share.


Other Segment Market Share Q2 2020

despite revenue deterioration, Abbvie Inc inceased its market share in this segment.

company inceased its market share in this segment to approximate 4.15 %.

<<  More on ABBV Market Share.

*Market share is not actual measurement, only performance comparison of companies which report and operate within the same segment.

ABBV's vs. Competition, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

Abbvie Inc ABBV 148,411 36,470 6,093 26,000
Abbott Laboratories ABT 190,749 31,444 3,110 77,000
Amgen Inc AMGN 146,650 32,341 7,299 17,900
Biogen Inc BIIB 44,164 14,487 5,985 7,550
Bristol Myers Squibb Co BMY 125,949 34,862 -540 25,000
Celgene Corp CELG 78,961 16,982 1,834 6,012
Cephalon, Inc. CEPH 0 0 0 0
Johnson and Johnson JNJ 397,639 80,503 15,185 126,500
Pfizer Inc PFE 205,824 49,197 14,201 78,300
Wyeth WYE 0 0 0 0
Gilead Sciences Inc GILD 81,638 22,174 -287 7,000
Merck and Co Inc MRK 218,306 47,193 10,500 70,000
Actavis Plc ACT 4,568 10,573 -751 19,200
Watson Pharmaceuticals Inc WPI 0 0 0 0
Bard C R Inc BCR 28,675 5,308 690 13,900
Eli Lilly And Company LLY 140,433 22,950 5,618 39,135
Mylan N v MYL 8,136 16,851 271 25,000
SUBTOTAL 1,820,104 421,335 69,207 538,497


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production


Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales


Event Calendar

BICX's Profile

Stock Price

BICX's Financials

Business Description


Charts & Quotes

BICX's News


BICX's Competitors

Customers & Markets

Economic Indicators

BICX's Growth

Company Segments


Stock Performance

Growth Rates




Financial Strength


Largest Companies

Management Effectivness


At a Glance


Growth Rates



Financial Strength


At a Glance



Sectors & Industries





At a Glance








About us


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.  Free Stock Market News Feeds
   Copyright © 2020 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

To view Intraday Stock Data Java must be installed. Java content may be prohibited by the security software, to see the stock quotes, choose "allow content from this page" option. Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071